Table 2 Characteristics of hypertensive PLHIV at baseline (N = 3892)
Characteristic | Patients not enrolled in the cohort (n = 2759) | Patients enrolled in the cohort (n = 1133) | P-value |
|---|---|---|---|
Age in years, mean (SD) | 44.7 (10.2) | 50.2 (9.6) | < 0.001 |
Age categories, count (%) | |||
 18–29 | 157 (5.7) | 15 (1.3) | 0.001 |
 30–39 | 753 (27.3) | 144 (12.7) | |
 40–49 | 1013 (36.7) | 400 (35.3) | |
 50 and older | 836 (30.3) | 574 (50.7) | |
Gender, count (%) | |||
 Male | 1084 (39.3) | 427 (37.7) | 0.210 |
 Female | 1675 (60.7) | 706 (62.3) | |
Baseline BP in mmHg, mean (SD) | |||
 Systolic | 143.0 (15.2) | 154.2 (20.8) | < 0.001 |
 Diastolic | 92.6 (9.3) | 97.8 (13.3) | < 0.001 |
Baseline BMI, count (%) (n = 3730) | |||
 Underweight (< 19.0) | 254 (9.2) | 62 (5.5) | < 0.001 |
 Normal weight (19.0 to < 25.0) | 1258 (45.6) | 392 (34.6) | |
 Overweight (25.0 to < 30.0) | 739 (26.8) | 376 (33.2) | |
 Obese (> 30.0) | 508 (18.4) | 303 (26.7) | |
Baseline CD4 category, count (%) | |||
 < 50 | 353 (12.8) | 127 (11.2) | < 0.001 |
 50 to < 100 | 207 (7.5) | 70 (6.2) | |
 100 to < 200 | 359 (13.0) | 213 (18.8) | |
 ≥ 200 | 1840 (66.7) | 723 (63.8) | |
Baseline ART regimen, count (%) (n = 3878) | |||
 AZT-3TC-NVP | 930 (33.7) | 480 (42.4) | < 0.001 |
 AZT-3TC-EFV | 331 (12.0) | 211 (18.6) | |
 TDF-3TC-NVP | 212 (7.7) | 110 (9.7) | |
 TDF-3TC-EFV | 974 (35.3) | 268 (23.7) | |
 Others | 312 (11.3) | 64 (5.6) | |
ART duration (years) | |||
 < 2 years | 568 (20.6%) | 51 (4.5%) | < 0.001 |
 2–5 years | 748 (27.1%) | 239 (21.1%) | |
 5–10 years | 1179 (42.7%) | 539 (47.6%) | |
 > 10 years | 264 (9.6%) | 304 (26.8%) | |